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Relevance statement 
Collaborative care integrates physical and mental healthcare. It is more effective than usual care for 
managing depression over the long term in people with co-existing mental and physical health 
conditions (mental-physical multimorbidity). This is the first long-term evaluation of collaborative 
care for managing mental-physical multimorbidity in a UK setting. Additionally, collaborative care is 
good value for money over the long-term and has the potential to deliver important health gains at 
levels generally considered to be cost-effective.  
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ABSTRACT 
Background  
Collaborative care can effectively support the treatment of depression in people with multiple long-
term physical conditions or mental-physical multimorbidity, but long term benefits and costs are 
unknown.  
 
Aims 
To explore the long-term effectiveness and cost-effectiveness of collaborative care in people with 
mental-physical multimorbidity. 
 
Method 
A cluster randomised trial of 36 general practices in England compared collaborative care with usual 
care (standard management by primary care staff) for people with depression and comorbid diabetes 
and/or coronary heart disease. Collaborative care included up to eight sessions of low-intensity 
psychological therapy with lifestyle/disease management advice (integrated physical and mental 
health care). Depression symptoms were measured using the symptom checklist-13 depression scale 
(SCL-D13) 24 months after baseline. The EQ-5D-5L was used to capture health status and calculate 
quality adjusted life years (QALYs) for the economic evaluation from the perspective of the National 
Health Service (NHS) in England. 
 
Results 
191 participants were allocated to collaborative care and 196 to usual care. At 24-months the mean 
SCL-D13 score was 0.27 (95% CI -0.48, -0.06) lower in participants in the collaborative care arm. 
Collaborative care was also associated with a QALY gain of 0.14 (95% CI 0.06, 0.21); the cost per 
additional QALY gained was £13,069. There is a 75% probability that collaborative care is cost-
effective at a threshold of £20,000/QALY. 
 
Conclusions 
Integrated collaborative care effectively reduces depression over the long term and can improve 
physical functioning. Collaborative care is potentially cost-effective over the long-term at 
internationally accepted willingness to pay thresholds.  
 
Declaration of interests 
None.  
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Introduction 
Multimorbidity refers to the presence of two or more long-term conditions, which can include 
combinations of physical and mental symptoms. Multimorbidity is a critical burden on health systems, 
associated with increased mortality, reduced quality of life, and increased use of unscheduled care.
1,2
 
The greatest reductions in quality of life are experienced by those with mental-physical 
multimorbidity
3
 which is associated with 45-65% higher costs of care for long-term conditions.
4
 
Collaborative care is a model of care for people with co-occurring mental and physical health 
conditions which recognises the interplay between the two. The most widely accepted current 
definition of collaborative care includes four key criteria: a multi-professional approach to patient 
care, a structured management plan, scheduled patient follow-ups, and enhanced inter-professional 
communication.
5
 A key element is the appointment of a care manager who acts as a conduit between 
patients and healthcare professionals, and works with the patient to promote better patient self-care.
6
 
There is some evidence that compared with usual care, collaborative care is more effective for treating 
depression and anxiety over the short- to medium-term, with or without multimorbid long-term 
conditions,
7
 but effectiveness beyond 12 months remains uncertain. The UK National Institute for 
Health and Care Excellence (NICE) concluded that there is currently an absence of clinical or cost-
effectiveness evidence for collaborative care in multimorbidity.
8
 In the context of interventions for 
long-term health conditions it is especially important to evaluate long-term clinical effectiveness and 
cost-effectiveness. This paper reports the long-term (24-month) clinical and cost-effectiveness of 
collaborative care for people with depression in the context of high levels of multimorbidity as part of 
the Collaborative Interventions for Circulation and Depression (COINCIDE) trial.  
 
Methods 
Trial design and participants 
The COINCIDE trial evaluated the clinical effectiveness of collaborative care over a short-term (4 
months) period. Collaborative care was associated with a significantly greater improvement in 
depression symptoms compared with usual care (effect size 0.30).
9
 The study protocol  (Trial 
Registration Number: ISRCTN80309252) has been published previously.
6,10
  
 
The evaluation was a two-arm cluster randomised controlled trial in the North West of England. 
Participating general practices held electronic registers of patients with diabetes and/or coronary heart 
disease and were assigned a unique identifier. 459 general practices across the north-west of England 
were invited to participate and 39 were allocated in a phased approach across the region (9 in 
Merseyside; 19 in Greater Manchester; 8 in East Lancashire); three practices withdrew before 
participants were recruited. Designated staff based remotely at the Clinical Trials Unit at the Christie 
NHS Foundation Trust, Manchester, UK provided a central randomisation service. A computer 
random number generator was used. The first six practices recruited were allocated 1:1 at random to 
either the collaborative care or usual care arm. Subsequent practices were then allocated using 
minimisation (with a probability weighting of 0.8),
11
 based on Index of Multiple Deprivation and 
practice list size. An email confirmation of allocation details were sent to the trial manager. Research 
staff were blind to the allocation of enrolled participants. Details of sample size calculations are 
reported in full elsewhere,
9
 the trial had 79% power to detect an effect size of 0.4. 
 
Staff from the National Institute for Health's Mental Health Research Network searched clinical 
databases at participating practices for patients with a record of diabetes and/or coronary heart 
disease. Patients who met these eligibility criteria were sent a postal invitation followed by a reminder 
letter three weeks later; non-responders to the reminder postal invitation were telephoned. Patients 
were screened for depressive symptoms (≥ 10 on the nine-item patient health questionnaire; PHQ-9)12 
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by the research team over the telephone twice over two weeks. Patients who met these criteria for at 
least two weeks were eligible to participate. We excluded patients with psychosis, type I or type II 
bipolar disorder; those who were actively suicidal; those in receipt of services for substances misuse; 
or receiving psychological therapy for depression from a mental health service. Full details of the trial 
design are reported in detail in the published protocol.
6,10
  
 
Ethical approval 
National Research Ethics Service Committee North West - Preston (NRES/11/NW/0742) granted 
ethical approval and research governance approvals were granted by participating primary care trusts. 
Informed consent was obtained in writing from all participants prior to data collection. 
 
Interventions 
Participants attending GP practices allocated to the collaborative care arm received up to 8 face-to-
face sessions over 3 months of brief psychological therapy delivered by a case manager.
6,10
  Case 
managers were ‘psychological well-being practitioners’ (PWPs) employed by Improving Access to 
Psychological Therapy (IAPT) services, given specific training in delivering the COINCIDE 
collaborative care model. The first session was expected to last 45 minutes during which the PWP 
identified links between participants’ mood and management of their long-term conditions with the 
aim of formulating a problem statement. Subsequent treatment sessions were scheduled to last for 30-
40 minutes and participants could choose to engage with behavioural activation, graded exposure, 
cognitive restructuring, and/or lifestyle changes. A ten minute collaborative meeting (by telephone or 
in person) between the participant, PWP, and a practice nurse from the participant’s general practice 
was scheduled to take place during treatment session two and eight to facilitate the integration of care. 
These collaborative meetings focused on ensuring that psychological treatments did not complicate 
current management, reviewing patients’ progress, reviewing relevant physical and mental health 
outcomes, and planning future care.
9
 The final session also included education about relapse 
prevention strategies. PWPs were expected to liaise with the practice nurse and participants’ GP about 
medication and update on participant progress. Participants attending general practices allocated to the 
control arm received treatment as usual based on the NICE stepped care model, provided by 
participants’ GP.13 This could include treatment of depression with medication and/or onward referral 
to psychological therapy. If participants in the usual care arm were referred to psychological therapy 
provided for by IAPT services they did not receive such care from COINCIDE trained PWPs. 
 
Outcomes 
The primary outcome was self-reported depression severity on the 13 depression items of the 
Symptom Check List-90 scale (range 0 to 4) 24 months after randomisation.
14
 Data on healthcare 
utilisation were collected using a bespoke patient questionnaire. Health status was measured using the 
Euroqol-5D-5L (EQ-5D-5L).
15
 All baseline measures were collected face-to-face by research staff 
blind to allocation; self-reported outcome measures at 24-months were collected by postal 
questionnaires. Participants who did not return the 24-month questionnaire were contacted by 
telephone and given the opportunity to complete the primary outcome over the telephone with a 
researcher blind to allocation.  
 
For economic analyses we used the UK National Health Service (NHS) and personal social services 
perspective in line with NICE guidance for economic evaluations of healthcare interventions.
16
 The 
time horizon for the economic evaluation was 24 months. Data on resource utilisation were collected 
at four months (covering the period between baseline and four months) and 24 months (covering the 
period between 4 and 24 months). Therefore it was not possible to distinguish which visits occurred in 
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the period between 4 and 12 months and which occurred between 12 and 24 months. For this reason 
costs associated with healthcare utilisation beyond 12 months were not discounted. For comparability, 
outcomes were also not discounted. 
Use of healthcare services was collected by asking participants to report their total number of visits to 
different healthcare professionals in these categories: inpatient admission, outpatient, day case (non-
overnight hospital admission), accident and emergency, and primary/ community care (e.g. GP, nurse, 
social worker). Direct costs were also estimated for the intervention. Data on the resources used to 
provide the intervention only were collected from activity logs completed by PWPs and practice 
nurses who delivered care to participants in the collaborative care arm. The costs of training PWPs 
were also included in the primary economic analysis. We based PWP costs on NHS Agenda for 
Change salary band four (current salary range £19,217– 22,458; US$24,271–28,364; €21,793–25,469) 
and included employer National Insurance and pension contributions plus capital, administrative, and 
managerial costs. We calculated cost per hour using standard working time assumptions,
17
 weighted 
to account for time spent on non-patient-facing activities. For each type of resource the cost was 
estimated as the quantity of that resource or service used multiplied by nationally applicable unit 
costs.
17,18
 All direct costs are reported in British pounds (£) and inflated to 2015/16 prices using the 
hospital and community health services (HCHS) index.
17
  
The primary measure of cost-effectiveness was cost per QALY.
16
 Utility values were derived at each 
time point from the EQ-5D-5L and associated utility tariffs for the UK, generated from a series of 
time trade off (TTO) and discrete choice experiments.
19
 The EQ-5D-3L crosswalk method
20
 was used 
to estimate utility values as a sensitivity analysis. A mean utility value was calculated for each set of 
two time points (baseline to 4 months; 4 to 24 months). The mean utility value and length of the 
respective time period (e.g. a utility value of 1 is equivalent to 0.5 QALYs if accrued over 6 months 
or 1 QALY if accrued over 12 months) was used to generate two QALY values (one for each time 
period) which were combined to estimate the total QALYs during the whole follow-up period.  
Statistical analysis  
We used an intention to treat approach for all clinical and cost-effectiveness analyses as per the 
original data analysis plan shared with the Data Monitoring and Ethics Committee. All analyses were 
conducted using Stata (Release 13). The trial originally had 80% power (2-sided α=0.05) to detect a 
difference between groups on the primary outcome at follow-up, equivalent to a standardised effect 
size of 0.4, for which we required 15 practices per arm and 15 patients per practice (n=450), allowing 
for 20% attrition and an intra-practice correlation of 0.06. Average recruitment in the first 11 practices 
was less than 15 patients per practice. We therefore increased the total number of clusters from 30 to 
36, with a target of ten patients per practice, giving 79% power to detect an effect of 0.4 under the 
same assumptions. The revised target sample was therefore 360 patients.
10
  
To compare the change in depression scores between participants randomised to collaborative care or 
usual care, multiple linear regression with robust standard errors was used; this accounted for the 
clustering of patients within practices. The following baseline characteristics were controlled for: 
depression score, age, sex, area deprivation (based on residential postcode), level of limitation of daily 
activities at baseline, use of antidepressants or antianxiety drugs (currently, previously, never), GP 
practice list size, and GP practice area deprivation (the latter two as ‘design factors’). Multiple 
imputation was used to estimate missing scale scores and other data values at both baseline and 
follow-up. Thirty imputed datasets were generated using chained equations including covariates as 
listed above. As part of the imputation model missing SCL-D13 values were restricted to between 0-4 
in line with the possible questionnaire responses. To assess sensitivity of the results to multiple 
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imputation we conducted secondary analyses on complete cases, firstly with the same covariates as 
the main analysis and secondly with only baseline depression score included as a covariate. A further 
post hoc sensitivity analysis was conducted without restricting the range of imputed SCL-D13 values. 
 
Economic analysis  
The base-case (primary) economic analysis calculated incremental cost effectiveness ratios (ICERs); 
accordingly, no parametric statistical tests of differences in mean costs or outcomes were conducted. 
Net QALYs (collaborative care versus usual care) were estimated using a linear regression model and 
net costs were estimated using a generalised linear regression model (GLM) with a log link and 
gamma family to allow for the non-normal distribution of costs. Regression models were adjusted for 
baseline variables identified through stepwise regression: World Health Organisation Quality of Life 
instrument (WHO-QoL), GAD-7, PHQ-9, self efficacy questionnaire (SEQ), health education impact 
questionnaire (heiQ), Sheehan disability scale (SDS), employment status, mobility (EQ-5D). Robust 
standard errors were used to account for the clustering of patients within practices. The estimates of 
incremental costs and outcomes from the regression were bootstrapped to simulate between 2,000 and 
10,000 pairs of net cost and net outcomes for a cost effectiveness acceptability analysis, as 
recommended by NICE for health technology appraisals.
16
  
Missing data on costs (cost per day) and EQ-5D-5L utility scores were imputed five times using a 
chained-equation procedure. Costs were imputed by category and utility by individual EQ-5D-5L 
domain, rather than as totals so that all available data were used to inform the imputed values. The 
pattern of available cost and utility data across the different assessments are summarised in 
supplementary material (Table S1). For the 24-month assessment, 69% of the original sample had a 
cost recorded for at least one category of healthcare and 69% had responded to at least one item on the 
EQ-5D. All available (complete and partial) cost and outcome data for a particular participant was 
used to impute missing data. The number of imputed datasets was chosen for pragmatic reasons, it 
was felt that this represented a balance between robustness and the computational burden of 
conducting the bootstrapping procedure on imputed data. 
 
Sensitivity analyses assessed the impact of design and analysis choices on the cost effectiveness of 
collaborative care. These were: an alternative method for utility/QALY estimation (crosswalk 
approach),
20
 a complete case analysis, an alternative measure of health benefit (proportion of 
participants showing a 'response' - 40% improvement from baseline in SCL-D13 depression score),
21
 
excluding the cost of training the PWPs, and number of bootstrap simulations. 
Results 
We invited 459 practices and allocated 39 practices, 19 to collaborative care and 20 to usual care; 3 
withdrew before patients were invited to take part. We identified 387 patients with depression and 
heart disease and/or diabetes and invited them to a baseline assessment. Follow-up data on 350 (90% 
of original sample) participants were collected at four-months between 18th November 2012 and 4th 
Oct 2013 and follow-up data on 272 participants (71% of original sample) were collected at 24-
months between 18th May 2014 and 4th June 2015 (see supplementary material for CONSORT 
diagram). Characteristics of participating practices and participants are reported in Table 1. The 
majority (63%) of participants at baseline met criteria for moderately severe or severe depression, and 
75% of participants met criteria for anxiety. Participants reported a mean of 6.2 (SD 3.2) long term 
conditions in addition to either diabetes or coronary heart disease; 15% of participants had a diagnosis 
of both diabetes and coronary heart disease. The mean age was 58.5 years and 38% of participants 
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were female. Around half (54%; n=211) of participants lived in areas ranked as highly deprived 
(index of multiple deprivation score ≥30). Twenty-five per cent of participants were in paid 
employment. Half of participants were prescribed anti-depressant or anti-anxiety medication at 
baseline. Full details about the delivery of the intervention have been previously reported.
9
  
 
Table 1 
 
For the primary outcome measure, depression scores were available at 24 months for 62% of 
participants allocated to the collaborative care arm and 74% allocated to usual care. The primary 
measure of health benefit for the economic evaluation was completed by 61% of collaborative care 
participants and 68% of usual care participants at 24 months. Across the categories of healthcare 
utilisation, 70-83% of participants had complete data at four months and 64-68% at 24 months. 
However when combined into a total cost 34% of the collaborative care group and 40% of the usual 
care had data for all of the categories at both time points. An additional summary of available cost and 
utility data is reported in supplementary material (Table S2). 
 
The unadjusted difference in mean SCL-D13 depression scores between baseline and first follow-up 
showed an improvement in both groups (four-month improvement: collaborative care 0.61; usual care 
0.31) (Table 2 and Figure 1a). When compared with baseline values, 24-month depression scores 
were again lower in both groups with the greater improvement maintained in the collaborative care 
arm (24-month improvement: collaborative care = 0.84; usual care = 0.55). 
 
After adjustment for covariates the mean SCL-D13 depression score at 24-month follow-up was 0.27 
points lower (95% confidence interval -0.48 to -0.06; p = 0.014) in participants who received 
collaborative care compared with those who received usual care. This difference is equal to a 
standardised mean difference of -0.35 (95% CI -0.62 to -0.05), using the baseline pooled SD for SCL-
D13. Collaborative care was also found to be significantly more effective than usual care at 24 months 
in all sensitivity analyses, although there was very little difference in the estimated coefficients 
between models (Table 2). 
 
Table 2 
 
Cost-effectiveness 
The mean cost of the collaborative care intervention was £321, including a training cost of £130 per 
participant (total training costs divided by the total number of participants randomised to collaborative 
care irrespective of number of PWP sessions attended). For participants with complete cost data at all 
time points, the mean cost across all categories of healthcare was higher among those randomised to 
collaborative care; the cost of healthcare resources used were higher across all categories except day 
case hospital visits and A&E (emergency) visits (see Supplementary Material - Table S3). 
  
Unadjusted mean health state index show that the usual care group worsened overall between baseline 
and 24 months (Figure 1b; also Supplementary Material - Table S3). The collaborative care group 
improved between baseline and first follow-up, which was sustained at the 24-month follow-up.  
 
Figure 1 
 
Regression analysis on multiple imputed datasets also showed a higher net cost associated with 
collaborative care (compared to usual care); £1777 (95% CI -£320 to £3875) over 24 months although 
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this difference is not statistically significant. Participants receiving collaborative care accrued 
significantly more QALYs over 24 months than those receiving usual care (0.136; 95% CI 0.061, 
0.212). The bootstrapped estimates of net costs and QALYs are shown on a cost-effectiveness plane 
in Figure 1c. The simulations are predominantly located in the upper-right quadrant of the plane 
indicating a net cost associated with collaborative care alongside a net health benefit (QALY gain). 
The points on the plane show more vertical than horizontal spread, illustrating that there is greater 
uncertainty around the estimated net cost than the estimated net benefit.  
 
The cost per additional QALY gained from collaborative care (compared to usual care) is £13,069. 
The probability of collaborative care being cost-effective is 0.75 if decision-makers are willing to pay 
£20,000 to gain one QALY. If decision-makers are willing to pay £30,000 to gain one QALY, the 
probability that collaborative care is more cost-effective than usual care is 0.92. This is shown in the 
cost-effectiveness acceptability curve (CEAC) in Figure 1d.  
 
Table 3 
 
There was little difference in the 95% confidence intervals generated from non-parametric 
bootstrapping 2,000 or 10,000 pairs of net costs and benefits, and no impact on the cost-effectiveness 
recommendation (Table 3). When the crosswalk method was used for estimating utility values from 
the EQ-5D, the net QALYs were slightly lower than for the time trade off approach (0.118 vs. 0.136), 
resulting in a slightly higher ICER (£15,063/QALY versus £13,069/QALY). When only participants 
with complete cost and QALY data were included in the analysis net costs were higher and net 
QALYs lower than the primary (base-case) analysis. This resulted in an ICER of £38,032 per QALY 
at which collaborative care would be unlikely to be more cost-effective than usual care (probability 
0.42 at a willingness-to-pay threshold (WTPT) of £30,000). When the measure of health benefit was 
the number of people showing a clinical response in terms of depression symptoms (40% reduction in 
total SCL-D13 score
21
 between baseline and 24 months), there were 50 more 'responders' in the 
collaborative care group. Alongside the net cost of £1777, the cost per each additional responder was 
estimated to be £36. There is no guidance on how much decision-makers are willing to pay for a 
treatment response therefore it is not meaningful to calculate a probability of cost-effectiveness in 
terms of this outcome measure. 
Discussion 
Collaborative care for depression in the context of multimorbidity is clinically and cost-effective over 
the long term. Not only were the treatment effects of collaborative care maintained over 24 months 
but they marginally exceeded those reported at four-months (standardised mean difference 0.35 versus 
0.30). Collaborative care was also associated with superior QALY gains compared with usual care 
(i.e. when both mental and physical domains of health are considered) in this context.  
 
This is the first long-term evaluation of collaborative care for managing mental-physical 
multimorbidity in a UK primary care setting. The net QALY gain observed in COINCIDE at 24 
months was greater than that observed in a previous economic evaluation of collaborative care in UK 
primary care.
22
 We previously reported results of an economic model estimating the long-term cost-
effectiveness of collaborative care, based on data observed at four months in the COINCIDE trial.
23
 
The net QALY gain observed here from 24-month trial data (0.14) was similar to the modelled 
scenario which assumed that the benefit of collaborative care accrued at four months would be 
maintained at the same level over 24 months (net QALY gain 0.15). Our findings here support this 
assumption; the mean utility values were similar at four and 24 months in the collaborative care 
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group, although the ICER estimated from the model was somewhat lower than for the 24-month trial 
data (£3468/QALY [model] versus £13,069/QALY [trial]).  
 
An important difference between the economic model and observed data is the estimated net cost. Net 
costs were notably higher using data observed within-trial, meaning that the additional healthcare 
resources used by participants randomised to collaborative care was greater than expected. 
Participants in the collaborative care arm used almost £1800 more of healthcare resource over 24 
months (crudely £900 over 12 months) than those receiving usual care. By comparison in the CADET 
trial the cost of healthcare resources over 12 months were almost identical between usual and 
collaborative care treatment groups.
22
 The unexpectedly high resource use might partly be explained 
by participants in the collaborative care arm reporting improved navigation of health services and 
more engagement with health directed behaviours, as evidenced by higher ratings on the health 
education impact questionnaire, compared to usual care.
9
 This may have led to increased but more 
appropriate use of healthcare resources and thereby improved levels of both physical and mental 
functioning.  
 
Strengths and limitations  
COINCIDE was a large pragmatic trial conducted across a wide geographical area in the north west of 
England that included a population with high levels of multimorbidity, disability, and deprivation. 
This makes it particularly relevant to the management of mental-physical multimorbidity which is 
more prevalent in younger adults from deprived regions.
24
 Cluster randomisation and analytic 
approaches for imputing data and adjusting for baseline characteristics offered greater opportunities to 
minimise bias and confounding. Additionally the 24 month follow-up period is the longest time 
horizon used in an integrated economic and effectiveness evaluation of collaborative care outside the 
United States. 
 
Our economic analysis conforms to the high standards of analysis and reporting expected of cost-
effectiveness analyses of health interventions (see Supplementary Material for CHEERS statement). 
However, data was not captured at baseline regarding use of health services prior to the intervention 
so it is not possible to determine or adjust for any underlying differences between the treatment 
groups. 
 
While multiple imputation of missing data reduced the potential for bias associated with missing data 
the robustness of any imputation method declines as the level of missing data increases, reducing the 
validity and reliability of the analyses. Data from baseline and 24-months only were included in the 
clinical effectiveness analysis and there was little difference in the change in depression score or 
effect size between the complete case analysis and the analysis following multiple imputation. The 
attrition rate was higher among participants in the collaborative care group (37.7%) compared to usual 
care (26.0%). We have explored key characteristics between participants with and without complete 
data (results not shown) and found only that in the usual care group, the mean age was higher (66 
years) for those with incomplete data for the primary outcome measure than those with complete data 
(59 years). There were no other differences. Age was adjusted for in all analyses and included in the 
multiple imputation model therefore this is unlikely to have unduly biased our results. 
 
The economic evaluation included cost and utility data from baseline, four months, and 24 months 
therefore there was greater scope for data to be missing. The proportion of participants with complete 
cost or utility data for all three time points (baseline, 4 months, 24 months) was lower than at the final 
time point (24 months) alone suggesting that missing data items rather than loss to follow-up 
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contributed to the level of missing data. Almost 70% of participants had complete cost or utility data 
however the proportion of participants with data for both was lower. As described in the methods, all 
available data were used to inform the imputed values and the role of multiple imputation can be 
thought of as filling in the blanks. A post hoc comparison of the characteristics of the participants 
with complete/incomplete economic data showed that only ethnicity was significantly different - there 
was a higher proportion of non-white participants with complete data than incomplete data (see 
supplementary material Table S2). This was surprising because for the participants who did not return 
the 24-month postal questionnaire, only English-speakers were able to complete it over the telephone 
(due to limited resources). The cost-effectiveness results were somewhat sensitive to missing data. 
The direction of the effect on costs and QALYs were the same, but the cost to gain one QALY was 
higher in the complete case analysis. 
 
Data on depression symptoms (SCL-D13), health status (EQ-5D), and healthcare resource utilisation 
were self-reported by participants. While pragmatic, self-reported methods are potentially prone to 
recall bias over a long-term follow-up. This is especially true in relation to capturing healthcare 
utilisation, particularly among those who use a large number of different healthcare services.  
However use of costly services (e.g. an inpatient admission or major surgery) are notable events and 
likely to be recalled even over a long period.
25,26
 Furthermore the intervention in this trial was not 
expected to have an impact on recall of healthcare utilisation. Although total costs may be an 
underestimation this is expected to be to the same extent in both groups and unlikely to influence the 
net cost. The second follow-up (at 24 months) had not been funded at the time of writing the original 
protocol for the COINCIDE trial and so participants were only approached for second follow-up after 
the original study period had ended. If it had been possible to inform participants about the second 
follow-up earlier, the attrition rate may have been lower. However a 68% retention rate over 24 
months for the primary outcome measure is acceptable and as described above multiple imputation 
was used to minimise the impact of missing data. Additionally, we were only resourced to collect 
long-term follow-up data for the primary and economic outcomes making it impossible to address 
questions about the long-term impact of the intervention on secondary outcomes evaluated in our 
short-term analysis.
9
 
 
Implications 
A strong case for routinely using collaborative care as a framework of care for depression was made 
by the CADET trial.
22,27
 We have since shown that collaborative care is as effective in people with 
long term conditions as it is in people with depression alone.
7
 However current NICE guidance about 
the management of multimorbidity has excluded evidence from interventions which primarily target 
depression. Their rationale for this was that any benefits for physical health may be an indirect effect 
of improvements in mood. While COINCIDE was designed as a depression intervention it has been 
identified as an approach that can effectively integrate the mental and physical healthcare of people 
with multimorbidity in primary care.
28
 In COINCIDE collaborative care improved both depression 
and physical functioning in people with multimorbidity. Furthermore, collaborative care is also likely 
to be cost effective over the long term. These findings address an evidence gap identified by NICE 
when developing their guideline/recommendations regarding the management of multimorbidity
8
 
 
Conclusion  
The need for cost-effective interventions for multimorbidity is of paramount importance in developed 
and developing regions faced with the burden of managing aging and/or deprived populations with 
complex health needs. Despite the limitations of this analysis, it can be concluded that collaborative 
care is clinically effective (with a moderate effect size) and cost-effective over the long-term as a 
12 
 
treatment for people with depression in the context of multimorbidity. In addition to existing 
evidence, findings from COINCIDE send a strong signal to clinicians and commissioners in primary 
care that collaborative care merits implementation to manage the impact of mental-physical 
multimorbidity over the long term. 
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Table 1 Baseline characteristics of COINCIDE practices and trial participants  
 
 Collaborative care 
(n=191) 
Usual care  
(n=196) 
 Number (%) Number (%) 
Practice deprivation 
Affluent 49 (26) 43 (22) 
Moderately deprived 80 (42) 90 (46) 
Heavily deprived 62 (33) 63 (32) 
Practice size 
Small (<4500) 60 (31) 49 (25) 
Medium (4500 to 7500) 61 (32) 41 (21) 
Large (>7500) 70 (37) 106 (54) 
Participant characteristics 
Age in years* 57.9 (12.0) 59.2 (11.4) 
Gender female 78 (41) 69 (35) 
Ethnicity white 162 (85) 167 (85) 
QOF register diabetes 106 (56) 101 (51) 
QOF register CHD 56 (29) 66 (34) 
QOF register diabetes and CHD 29 (15) 29 (15) 
 Mean (SD) Mean (SD) 
Deprivation IMD score (low score indicates 
high deprivation) 
36.6 (21.3) 34.4 (18.5) 
Number of long-term physical 
conditions**  
6.0 (3.2) 6.5 (3.1) 
PHQ-9 total depression score (0-27) 16.4 (4.2) 16.5 (4.1) 
GAD-7 total anxiety score (0-21) 12.3 (5.1) 11.9 (5.3) 
*mean (SD); **(excluding diabetes & CHD) 
QOF = quality outcomes framework; CHD = coronary heart disease. IMD = index of multiple 
deprivation; PHQ = patient health questionnaire; GAD=generalised anxiety disorder assessment  
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Table 2 - Mean depression scores (SCL-D13) at all time points and change in depression scores 
between baseline and 24 months  
 
 
 
Collaborative care Usual Care 
N Mean (SD) N Mean (SD) 
Baseline 191 2.364 (0.696) 196 2.330 (0.822) 
4 months 170 1.756 (0.938) 180 2.020 (0.935) 
24 months 119 1.527 (0.945) 145 1.785 (1.034) 
Attrition rate (baseline to 24 months) 37.7% 26.0% 
 Adjusted
*
 
difference in means  
Effect size 
 (95% CI); P-value (95% CI) 
Primary analysis 
Imputed data (n=387) -0.269  
(-0.476, -0.061) 
-0.353 
(-0.624, -0.047) 
Sensitivity analysis 
Complete cases (n=245) -0.264  
(-0.450, -0.078) 
-0.346 
(-0.454, -0.102) 
Complete cases (adjusted for baseline SCL-
D13 score only) (n=264) 
-0.260  
(-0.416, -0.104) 
-0.341  
(-0.546, -0.136) 
Imputed data, regression model not 
constrained to possible value range (0-4) for 
mean SCL-D13 (n=387) 
-0.260  
(-0.416, -0.104) 
-0.341 
(-0.546, -0.136) 
*Adjusted for all following covariates unless indicated otherwise: age, sex, socioeconomic 
deprivation, limitation of daily activities due to co-morbidities, use of antidepressants or anti-
anxiety drugs, and GP practice characteristics 
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Table 3 Net costs and QALYs, ICER and probability collaborative care is cost effective, 
primary and sensitivity analyses, adjusted for baseline covariates, bootstrapped and imputed 
data (unless otherwise stated)  
 
 Net cost  
(95% CI)  
Net QALY  
(95% CI)  
ICER 
(£/QALY) 
Probability collaborative care is 
cost effective versus usual care 
if WTPT =  
£15,000/ 
QALY 
£20,000/ 
QALY 
£30,000/ 
QALY 
Primary analysis        
Multiple imputation 
(n=387) 10,000 
bootstrap simulations 
1777  
(-320, 3875) 
0.136 
(0.061, 0.212) 
£13,069/QALY 0.58 
 
0.75 0.92 
Multiple imputation 
(n=387) 2,000 
bootstrap simulations 
1777  
(-313, 3867) 
0.136 
(0.061, 0.212) 
£13,069/QALY 0.57 0.75 0.92 
Sensitivity analyses (2,000 bootstrap simulations)   
QALYs estimated 
using crosswalk 
methodology 
20
 
1777  
(-313, 3867) 
0.118 
(0.001, 0.235) 
£15,063/QALY 0.49 0.63 0.78 
No imputation 
(complete cases, 
n=130) 
3347  
(-1119, 7813) 
0.088 
(-0.060, 0.237) 
£38,032/QALY 0.21 0.28 0.42 
Excluding PWP 
training costs 
1632 
(-457,3722) 
 
0.136 
(0.061, 0.212) 
£12,002/QALY 0.62 0.78 0.93 
  Number of 
responders  
(95% CI) 
Cost per 
additional 
person 
responding to 
treatment 
   
Health benefit - 
'response' on SCL-13 
 (40% improvement 
from baseline)
21
 
1777  
(-320, 3875) 
Usual care: 35 
(25-45) 
Collaborative 
care: 85 (72-98) 
Difference: 50 
£36*  - - - 
ICER = incremental cost-effectiveness ratio; WTPT=willingness to pay threshold 
*net cost (£1777) divided by number of additional responders (50) 
Covariates costs: baseline mobility (EQ-5D), GP practice (cluster) 
Covariates QALYs: baseline scores for WHO-QoL, GAD-7, PHQ-9, SEQ, heiQ, SDS, employment status, GP 
practice (cluster) 
 
 
